McKesson Corporation announced an agreement to acquire Precision Medicine Group for approximately $2.25 billion. The deal expands McKesson's clinical research and commercialization services, with Precision Medicine Group reporting within McKesson's Oncology & Multispecialty segment, which had first-quarter sales of $14.2 billion. Precision Medicine provides biomarker intelligence, lab services, a global clinical research organization, market access consulting, and commercialization support to biotechnology and pharmaceutical companies. McKesson ended the first quarter with cash and equivalents of $5.20 billion. McKesson shares were up 1.22% at $873.29 at the time of publication on Tuesday.
McKesson CorporationAcquires Precision Medicine Group for $2.25B, expanding services.
Being acquired by McKesson at $2.25B, providing value to shareholders.
